Venetoclax联合化疗治疗难治/复发急性髓系白血病8例并文献复习

Venetoclax combined therapy in 8 patients with refractory/relapsed acute myeloid leukemia and literature review

目的:评价短疗程Venetoclax(VEN)联合小剂量阿糖胞苷(ara-C)方案在难治/复发急性髓系白血病(AML)患者中的疗效和安全性。方法:报告8例以短疗程VEN+小剂量ara-C方案联合治疗的难治/复发AML患者。VEN使用剂量为200~400 mg QD口服,ara-C 10 mg/m2 Q12 h皮下注射,每疗程用药时间10~14 d。结果:8例患者初始治疗后3例达完全缓解,2例达部分缓解,3例评估为未缓解。治疗过程中发现幼稚单核细胞逐渐增多。发生的不良反应主要是3~4级血液学不良反应。结论:短疗程VEN联合小剂量ara-C方案治疗难治/复发AML患者有较好的有效率和安全性,但对急性单核细胞白血病疗效不佳。

Objective:To evaluate the efficacy and safety of short course venetoclax(VEN)combined with low dose cytarabine(ara-C)in patients with refractory or relapsed acute myeloid leukemia(AML). Methods:A report was performed among 8 patients with refractory or relapsed AML treated with short course VEN combination low dose ara-C.VEN was given at 200 to 400 mg orally every day,and ara-C was 10 mg/m2 subcutaneous injection every 12 hours. There were 10 to 14 days for each course of treatment. Results:After initial treatment,3 cases achieved complete response,2 case achieved partial response,and 3 cases had no response.In the course of treatment,we observed that the number of naive monocytes increased.The main adverse events were grade 3 to 4 hematological adverse events.Conclusion:Short course VEN combined with low dose ara-C regimen is effective and safe in the treatment of refractory or relapsed AML patients,but not effective in acute monocytic leukemia.